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Abstract: Adrenomedullin (AdM) is a novel
peptide that elicits a long-lasting vasorelaxant
activity. It is expressed in several tissues,
including adrenal medulla, heart, lung,
kidneys, and cultured vascular smooth muscle
cells. Also in large amounts, it is present in
amniotic fluid and cord blood. The aim of this
study was to assess placental AdM secretion
in preeclampsia. Placental tissues were
collected from seven preeclamptic patients
and ten healthy gravidas. Tissue
concentration of rat AdM was measured by
using reverse-phase high performance liquid
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Introduction
Preeclampsia is a major cause of maternal and
neonatal morbidity and mortality. Despite the ubiquity of
the disease and its public health impact, no
comprehensive mechanism has been established. The
most pathologically significant change in preeclampsia is
thought to be arteriolar constriction in general organ
systems. Blood pressure is controlled by a complex
network of various regulation systems because its
homeostatic balance is crucial to the maintenance of vital
activity. Among these systems, regulation of vascular
tone has been shown to be a major system controlling
blood pressure (1,2). AdM is a novel peptide that was
first isolated from human pheochromocytoma and it
elicits a long-lasting vasorelaxation (3). Several studies
suggest that AdM participates in the regulation of blood
pressure by different mechanisms
(3,4). The
immunohistologic distribution of AdM in human tissues
has shown the presence of AdM-immunoreactive cells in
pancreatic islets, the gastrointestinal neuroendocrine
system, and the anterior pituitary gland, indicating that
adrenomedullin-positive cells are widely distributed in the

chromatography (Cecil 1100). Mann Whitney
U test was used for statistical significance.
Significance was set at p<0.05. AdM
concentrations were 144.1±3.20 pmol/ml
and 178.7±4.4 pmol/ml in preeclamptics
and healthy gravidas respectively. This
difference was significant (p<0.05). These
data suggest that placental synthesis of AdM
in preeclampsia is reduced, and low
production of AdM may be responsible for
placental pathology in preeclampsia.
Key Words: Preeclampsia, adrenomedullin,
placental pathology.

endocrine and neuroendocrine systems where they may
play a role in the control of systemic and local circulations
and in humoral secretion (5). It was recently isolated
from second-trimester human amniotic fluid, amniotic
membranes of term pregnancies, and umbilical cord
blood (6,7). However, any roles that AdM plays in fetal,
placental, or maternal physiology have yet to be
elucidated. In this study, we investigated whether or not
AdM secretion is altered in the placental unit of those with
preeclamsia.
Materials and Methods
Tissues were collected from 10 healthy gravidas and 7
preeclamptic patients with singleton pregnancies in the
third trimester following delivery by elective cesarean
section. Samples were immediately stored at –30ºC until
analysis. For adrenomedullin measurement, the
specimens were minced on ice and then homogenized
with a polytron (Kinematica GmBH, Littau, Switzerland)
mixer at 4ºC, and the homogenate was centrifuged at
24000g for 30 minutes. The supernatant of the extract
was loaded onto a Supel-Cosil C-18 column (Sigma, CA),
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which was preequilibrated with 1 mol/L acetic acid, and
the absorbed materials were eluted with 4 mL of 50%
acetonitrile containing 0.1% trifluoracetic acid. Reverse
phase high pressure liquid chromatography was used for
measurement. Mann Whitney U test was used for
statistical analysis and statistical significance was set at
p<0.05.
Results
There was no difference between preeclamptic and
healthy gravidas in terms of mean age and gestational
age (24.3±3.1 vs 26.0± 1.2 and 35.9± 2.0 vs 37.1±
1.7, p > 0.05) respectively. Mean±SE adrenomedullin
concentrations were 144.1±3.2 pmol/ml and 178.7±4.4
pmol/ml in preeclamptics and healthy gravidas
respectively. This difference was significant (p<0.05).
Discussion
We found AdM concentration to be markedly lower in
placental tissue in preeclamptic patients, than in healty
gravidas. This implies that placental secretion of AdM is
decreased in preeclampsia. Recent studies have shown
that during pregnancy AdM levels gradualy increase and
the level of AdM is always higher than in nonpregnant
women (8-10). The physiologic significance of highly
increased AdM synthesis during pregnancy has yet to be
established. It has been demonstrated that AdM exerts
natriuretic action on peripheral vasculature and kidneys
to control fluid and electrolyte homeostasis and affects
angiotensin II (11). Thus it is possible that AdM is
involved in the process of adaptation of the vascular
system to pregnacy.
Morinoni et al. (8) demonstrated that AdM
concentrations detected in fetoplacental tissues is
comparable to those found in human adrenal medulla.
They showed that immunorective AdM staining in the
placenta was localized primarily in extravillous
trophoblast cells and in scattered areas of the
syncytiotrophoblast, although in most villi these results
appeared negative. Endothelial cells in chronic plate and in
primary villi vessels also stained for AdM. It was found
that arterial and venous umblical plasma concentrations
of AdM did not differ in uncomplicated pregnancies,
indicating that in normal state there is neither production
nor net clearence of AdM in the placenta (12). AdM,
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which is present in amniotic fluid, amnion membranes,
and the placenta, may play a role in the modulation of
fetal and maternal blood pressure and placental perfusion
through its well-known vasoactive properties (13,14).
AdM may affect endocrine secretion (15) and immune
response to microbial invasion (16). It was also found to
play a role as a modulator of cell growth (17) and to
enhance the availability of nutrients to support growth by
increasing blood flow (18). These same attributes of AdM
in tumor biologic features may also be vital in pregnancy.
The failure of normal implantation and development of
the placenta may be associated with abnormal fetal
growth, including IUGR and preeclampsia. AdM
stimulates DNA synthesis and cell proliferation of Swiss
3T3 fibroblasts, acting by means of elevation of
intracelular cyclic adenosine monophosphate (19), and
inhibits fetal calf serum-stimulated proliferation in
cultured rat vascular smooth muscle cells in a paracrine
fashion (20). Abnormal immune activation has been
suggested as a contributor to the development of
preeclampsia. Activated neutrophils and increased plasma
interleukin-12 were reported in preeclampsia
(10,21,22). From this point of view, one can argue that
decreased AdM levels may have deleterious effects as an
immunmodulator in preeclampsia. These data are of
particular importance in that low levels of placental AdM
in preeclampsia may be an explanation for the
development of hypertention and IUGR in preeclampsia.
Recently, it was reported that plasma AdM was not
different in preeclamptic and healty gravidas, but
placental AdM was higher in the preeclamptic group (23).
In another study, placental AdM was found to be lower in
the preeclamptic rat model (24). Since there are
conflicting results in the literature, further studies need
to be carried out.
In conclusion, the placental secretion of AdM is itself
defective in these patients, and this may play an
important role in the development of hypertension and
IUGR in preeclampsia. Further research should be done to
elucidate the pathophysiologic role of this peptide in
pregnancy.
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